Ceska Gynekol. 2020 Winter;85(3):222-225.
Methods of hormonal contraception are an important tool in the implementation of family planning. Although the primary design of hormonal contraceptives was based on a combination of estrogenic and progestogenic components, the most important component of hormonal contraceptives is the progestin molecule responsible for the anti-gonadotropic effect leading to ovulation inhibition, increased cervical mucus viscosity and endometrial desynchronization. The combination of progestins with estrogens has improved the bleeding profile, but it has increased the risk of cardiovascular complications, particularly deep venous thrombosis and pulmonary embolism, in patients at specific risk. The development of purely progestogenic contraceptives is being conducted to eliminate these cardiovascular risks. A new hormonal contraceptive based on oral drospirenone alone at a daily dose of 4 mg administered in a 24-active tablet + 4 days hormone-free interval shows contraceptive efficacy and bleeding profile consistent with combined hormonal contraceptives and high safety profile as the risk of deep vein thrombosis and pulmonary embolism does not increase according to recent clinical studies. It appears to be a very effective alternative to combination products suitable for a wide range of users.
避孕方法是实施计划生育的重要工具。虽然激素避孕药的主要设计是基于雌激素和孕激素成分的组合，但激素避孕药最重要的成分是孕激素分子，它负责抗促性腺作用，导致排卵抑制、宫颈粘液粘度增加和子宫内膜不同步。孕激素与雌激素的联合应用改善了出血模式，但增加了特定风险患者发生心血管并发症的风险，特别是深静脉血栓形成和肺栓塞。正在开发纯孕激素避孕药以消除这些心血管风险。一种新的基于每日 4 毫克口服屈螺酮的单纯孕激素避孕药，在 24 片活性片剂+4 天无激素间隔期内给药，显示出与复方激素避孕药一致的避孕效果和出血模式，并且具有较高的安全性，因为根据最近的临床研究，深静脉血栓形成和肺栓塞的风险没有增加。它似乎是一种非常有效的替代组合产品，适用于广泛的用户。
